1. Scrip

EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs

 
• By Jessica Merrill

With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.

Thinking big business concept as a large rocket blasting through the smoke of a group of jet air planes as a financial metaphor for corporate winner as a 3D render.
EEQRx hopes to disrupt industry's business as usual pricing model • Source: Shutterstock

A start-up with ambitions to disrupt the industry's long-standing drug pricing model could be a new threat to big pharma. EQRx has $200m in financing, a big-name leadership team and a mission to develop me-too drugs that cost a fraction of the cost of first-to-market brands.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business